Seeking Alpha

Celsion buys cancer therapeutics firm

  • Celsion (CLSN) acquires privately-held biopharmaceutical firm EGEN for $14M in cash and stock. EGEN focuses on the development of nucleic acid-based therapeutics for cancer and other difficult-to-treat diseases.
  • Under the terms of the acquisition agreement, Celsion will make an upfront payment of $10.6M in CLSN common stock and $3.4M in cash. $2.1M in stock will be held back for 24 months for expense adjustments and indemnification claims.
  • Celsion will owe an additional $30.4M to EGEN based on the successful completion of certain development and licensing milestones.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs